Free Cash Flow

With its 2026 Investor Day nearing, PHINIA aims to prove its dual-path strategy is the key to powering a diverse, carbon-conscious industrial future.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

A massive 320 MWh battery project in Belgium reveals how strategic investments in energy storage are becoming the ultimate luxury: grid stability and sustainability.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.

Antero Resources executes a complex asset swap, doubling down on the Marcellus Shale. We break down the financial engineering behind the multi-billion dollar deal.

Shipping giant Frontline secures a massive capital-raising mandate, signaling bold moves ahead. What does this mean for global energy and investors?

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

New clinical data on VALTOCO nasal spray shows significant benefits for young children, reinforcing the critical need for rapid seizure intervention.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

Beyond marble floors, the new luxury is a seamless, secure, and AI-driven transaction. We explore how tech is reshaping high-end property deals.

With its CFO departing after a major strategic pivot, AAR CORP. names a 13-year insider as his interim replacement. What does this signal for investors?